Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

3DCanPredict

Financiado

Cerrado

Predicting clinical response to anticancer drugs using 3D bioprinted tumor model...

Predicting clinical response to anticancer drugs using 3D bioprinted tumor models for personalized therapy Predicting clinical response to novel and existing anticancer drugs remains a major hurdle for successful cancer treatment. Studies indicate that the tumor ecosystem, resembling an organ-like structure, can limit the predictive po... ver más

28/02/2021

TAU

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

TEL AVIV UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-02-28

ERC-2019-POC: ERC Proof of Concept Grant

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

TAU

150.00K€ | Lider

X-RAY IMATEK

350.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-126523OB-I00 DESARROLLO DE UN MODELO TRIDIMENSIONAL DE MELANOMA DINAMICO,... 115K€ Cerrado

TechTissue TechTissue - Validate human-based 3D in vitro models for acc... 75K€ Cerrado

B2B Modeling spontaneous Breast cancer metastasis TO the Bone wi... 4M€ Cerrado

MicroBone Novel 3D platforms to engineer bone microtissues for in vitr... 150K€ Cerrado

MImETIC INDiRECT MIcrovascularizED Tumour on chip for Cellular ImagiNg of Dru... 197K€ Cerrado

3DBrainStrom Brain metastases Deciphering tumor stroma interactions in t... 2M€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2019-08-26
Fecha Fin: 2021-02-28

Líder del proyecto

TEL AVIV UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Predicting clinical response to novel and existing anticancer drugs remains a major hurdle for successful cancer treatment. Studies indicate that the tumor ecosystem, resembling an organ-like structure, can limit the predictive power of current therapies that were evaluated solely on tumor cells. The interactions of tumor cells with their adjacent microenvironment are required to promote tumor progression and metastasis, determining drug responsiveness. Such interactions do not form in standard research techniques, where cancer cells grow on 2D plastic dishes. Hence, there is a need to develop new cancer models that better mimic the physio-pathological conditions of tumors. Here, we create 3D-bioprinted tumor models based on a library of hydrogels we developed as scaffold for different tumor types, designed according to the mechanical properties of the tissue of origin. As PoC, we bioprinted a vascularized 3D brain tumor model from brain tumor cells co-cultured with stromal cells and mixed with our hydrogels, that resemble the biophysics of the tumor and its microenvironment. Our patient-derived models consist of cells from a biopsy, constructed according to CT/MRI scans, and include functional vessels allowing for patients' serum to flow when connected to a pump. These models will facilitate reproducible, reliable and rapid results, determining which treatment suits best the specific patient's tumor. Taken together, this 3D-printed model could be the basis for potentially replacing cell and animal models. We predict that this powerful platform will be used in translational research for preclinical evaluation of new therapies and for clinical drug screening, which will save critical time, reduce toxicity and significantly decrease costs generating a major societal benefit. Our platform offers a highly attractive business case, as pharmaceutical and biotech companies heavily invest in preclinical predictive tools for novel personalized drug screening strategies.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores